A clinical trial result showed that asthma attacks were dramatically reduced when albuterol (ingredient name), a drug taken by asthma patients, and budesonide (ingredient name), administered by inhaler, were used together for treatment.
This is from the results of the phase 3 clinical trial (test name: MANDALA) for the asthma treatment of AstraZeneca, a multinational pharmaceutical company.
According to the study, the combination therapy of albuterol and busonide reduced the number of symptomatic asthma attacks, including sudden dyspnea, wheezing (wheezing and growling), and cough.
Albuterol relieves asthma attacks by relaxing the smooth muscles of the airways (hidden) and is used for immediate asthma relief.
Also, budesonide is a corticosteroid (a type of corticosteroid) drug that is sucked through the nose.
When asthma patients have seizures, they are often taken to the emergency room or hospitalized, and in severe cases, they can even lead to death.
“The results of this study represent a paradigm shift in asthma treatment,” said Professor Reynold Panettieri, Rutgers University School of Medicine, Rutgers University School of Medicine, lead author of the clinical trial study. said
The research team conducted a Phase 3 clinical trial study on more than 3,000 asthmatics at 295 test centers across the United States, Europe, and South America.
This is to evaluate the safety and effectiveness of a combination therapy using AstraZeneca’s albuterol and budesonide together for moderate-to-severe asthma patients.
Albuterol is a fast-acting beta-2 agonist that binds to a very small protein called the ‘beta receptor’ in the airways and acts to relax the muscles.
Budesonide, a corticosteroid (a type of corticosteroid) drug, reduces swelling and irritation of the airways.
Standard ‘maintenance’ treatment involves administration of an inhaled drug that combines two drugs: a long-acting beta2 agonist such as beclomethasone and a corticosteroid such as beclomethasone.
When a patient has an asthma attack, an emergency medication such as albuterol is usually used. Sometimes oral steroids are prescribed. However, doctors are cautious about prescribing oral steroids because of the serious side effects.
The research team divided the patients into three groups and conducted a clinical trial. With many patients already on daily asthma maintenance therapy, participants in the group received one of three rescue therapies in case of an asthma attack.
The experimental group consisted of a group receiving a combination of albuterol and high-dose budesonide and a group receiving a combination of albuterol and low-dose budesonide. In addition, the control group received only albuterol.
Clinical trial results showed that asthma patients treated with albuterol and budesonide had improved lung function and fewer heart attacks.
Patients who took albuterol in combination with high-dose budesonide had a 27% reduction in the risk of short-term asthma attacks and a 24% reduction in the number of asthma attacks per year.
It has also been shown that this combination therapy can reduce the use of corticosteroids, which can cause side effects, by up to 33%.
“Patients can often receive more medications by inhaler when they have sudden asthma attacks, which reduces the number of asthma attacks and reduces the need to take oral steroids after attacks,” the research team said.
According to the Asthma Allergy Foundation (AAF), approximately 25 million adults and children in the United States suffer from asthma. In addition, according to the 2019 National Health Statistics in Korea, the prevalence of asthma over the age of 19 is 3.2%, and the prevalence of asthma over the age of 65 is 5.0%.
The results of this study were published in the New England Journal of Medicine and introduced by the American health and medicine media ‘MedicalXpress’.